{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:24:09Z","timestamp":1793046249776,"version":"4.5.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:00:00Z","timestamp":1690502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Takeda Development Center Americas, Inc"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-AI116635"],"award-info":[{"award-number":["R01-AI116635"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This drug resistance analysis of a randomized trial includes 234 patients receiving maribavir and 116 receiving investigator-assigned standard therapy (IAT), where 56% and 24%, respectively, cleared cytomegalovirus DNA at week 8 (treatment responders).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Baseline and posttreatment plasma samples were tested for mutations conferring drug resistance in viral genes UL97, UL54, and UL27.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, genotypic testing revealed resistance to ganciclovir, foscarnet, or cidofovir in 56% of patients receiving maribavir and 68% receiving IAT, including 9 newly phenotyped mutations. Among them, 63% (maribavir) and 21% (IAT) were treatment responders. Detected baseline maribavir resistance mutations were UL27 L193F (n = 1) and UL97 F342Y (n = 3). Posttreatment, emergent maribavir resistance mutations were detected in 60 (26%) of those randomized to maribavir, including 49 (48%) of 103 nonresponders and 25 (86%) of the 29 nonresponders where viral DNA initially cleared then rebounded while on maribavir. The most common maribavir resistance mutations were UL97 T409M (n = 34), H411Y (n = 26), and C480F (n = 21), first detected 26 to 130 (median 56) days after starting maribavir.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Baseline maribavir resistance was rare. Drug resistance to standard cytomegalovirus antivirals did not preclude treatment response to maribavir. Rebound in plasma cytomegalovirus DNA while on maribavir strongly suggests emerging drug resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p>NCT02931539.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiad293","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T08:49:16Z","timestamp":1690447756000},"page":"413-421","source":"Crossref","is-referenced-by-count":85,"title":["Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients"],"prefix":"10.1093","volume":"229","author":[{"given":"Sunwen","family":"Chou","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Oregon Health and Science University , Portland, Oregon , USA"},{"name":"Research and Development Service, Veterans Affairs Portland Health Care System , Portland, Oregon , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9787-1421","authenticated-orcid":false,"given":"Sophie","family":"Alain","sequence":"additional","affiliation":[{"name":"Department of Virology and National Reference Center for Herpesviruses, Limoges University Hospital, UMR Inserm 1092, University of Limoges , Limoges , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Cervera","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Alberta , Edmonton, Alberta , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy F","family":"Chemaly","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control, and Employee Health, University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille N","family":"Kotton","sequence":"additional","affiliation":[{"name":"Transplant and Immunocompromised Host Infectious Diseases, Infectious Diseases Division, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8901-7850","authenticated-orcid":false,"given":"Jens","family":"Lundgren","sequence":"additional","affiliation":[{"name":"Centre for Health and Infectious Disease Research, Department of Infectious Diseases, Rigshospitalitet, University of Copenhagen , Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genovefa A","family":"Papanicolaou","sequence":"additional","affiliation":[{"name":"Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, New York , USA"},{"name":"Department of Medicine, Weill Cornell Medicine , New York, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus R","family":"Pereira","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University Medical Center , New York, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyang J","family":"Wu","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. , Lexington, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose Ann","family":"Murray","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. , Lexington, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil E","family":"Buss","sequence":"additional","affiliation":[{"name":"Medical Expressions , B\u00fcren, Solothurn , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Fournier","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. , Lexington, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,28]]},"reference":[{"key":"2024021703072809300_jiad293-B1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMoa1714656","article-title":"Maribavir for preemptive treatment of cytomegalovirus reactivation","volume":"381","author":"Maertens","year":"2019","journal-title":"N Engl J Med"},{"key":"2024021703072809300_jiad293-B2","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/cid\/ciy706","article-title":"Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study","volume":"68","author":"Papanicolaou","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2024021703072809300_jiad293-B3","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial","volume":"75","author":"Avery","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024021703072809300_jiad293-B4","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1128\/AAC.46.8.2365-2372.2002","article-title":"Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole l-riboside with a unique mode of action","volume":"46","author":"Biron","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2024021703072809300_jiad293-B5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/rmv.615","article-title":"Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir","volume":"19","author":"Prichard","year":"2009","journal-title":"Rev Med Virol"},{"key":"2024021703072809300_jiad293-B6","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3390\/microorganisms8040515","article-title":"The cytomegalovirus protein kinase pUL97: host interactions, regulatory mechanisms and antiviral drug targeting","volume":"8","author":"Steingruber","year":"2020","journal-title":"Microorganisms"},{"key":"2024021703072809300_jiad293-B7","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/358162a0","article-title":"A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells","volume":"358","author":"Sullivan","year":"1992","journal-title":"Nature"},{"key":"2024021703072809300_jiad293-B8","doi-asserted-by":"crossref","first-page":"104711","DOI":"10.1016\/j.antiviral.2020.104711","article-title":"Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance","volume":"176","author":"Chou","year":"2020","journal-title":"Antiviral Res"},{"key":"2024021703072809300_jiad293-B9","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/rmv.574","article-title":"Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir","volume":"18","author":"Chou","year":"2008","journal-title":"Rev Med Virol"},{"key":"2024021703072809300_jiad293-B10","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/infdis\/jiaa462","article-title":"Drug resistance mutations and associated phenotypes detected in clinical trials of maribavir for treatment of cytomegalovirus infection","volume":"226","author":"Chou","year":"2022","journal-title":"J Infect Dis"},{"key":"2024021703072809300_jiad293-B11","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"Chemaly","year":"2014","journal-title":"N Engl J Med"},{"key":"2024021703072809300_jiad293-B12","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1128\/AAC.01623-15","article-title":"Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance","volume":"59","author":"Chou","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2024021703072809300_jiad293-B13","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1128\/AAC.01794-13","article-title":"Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure","volume":"58","author":"Goldner","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2024021703072809300_jiad293-B14","doi-asserted-by":"crossref","first-page":"105139","DOI":"10.1016\/j.antiviral.2021.105139","article-title":"Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing","volume":"193","author":"Chou","year":"2021","journal-title":"Antiviral Res"},{"key":"2024021703072809300_jiad293-B15","doi-asserted-by":"crossref","first-page":"104616","DOI":"10.1016\/j.antiviral.2019.104616","article-title":"Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","volume":"172","author":"Chou","year":"2019","journal-title":"Antiviral Res"},{"key":"2024021703072809300_jiad293-B16","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1128\/AAC.01177-08","article-title":"Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir","volume":"53","author":"Chou","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2024021703072809300_jiad293-B17","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/infdis\/jit654","article-title":"Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial","volume":"209","author":"Chou","year":"2014","journal-title":"J Infect Dis"},{"key":"2024021703072809300_jiad293-B18","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1128\/JVI.01787-07","article-title":"Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant","volume":"82","author":"Chou","year":"2008","journal-title":"J Virol"},{"key":"2024021703072809300_jiad293-B19","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1128\/AAC.00334-11","article-title":"Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet","volume":"55","author":"Gilbert","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2024021703072809300_jiad293-B20","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jcv.2011.01.004","article-title":"Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy","volume":"50","author":"Chou","year":"2011","journal-title":"J Clin Virol"},{"key":"2024021703072809300_jiad293-B21","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1128\/JVI.72.7.5927-5936.1998","article-title":"Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments","volume":"72","author":"Cihlar","year":"1998","journal-title":"J Virol"},{"key":"2024021703072809300_jiad293-B22","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1093\/infdis\/jiab029","article-title":"Phenotype and genotype study of novel C480F maribavir-ganciclovir cross-resistance mutation detected in hematopoietic stem cell and solid organ transplant recipients","volume":"224","author":"Santos Bravo","year":"2021","journal-title":"J Infect Dis"},{"key":"2024021703072809300_jiad293-B23","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"2024021703072809300_jiad293-B24","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1177\/135965350901400510","article-title":"Conserved domains and structure prediction of human cytomegalovirus UL27 protein","volume":"14","author":"Hantz","year":"2009","journal-title":"Antivir Ther"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiad293\/51114614\/jiad293.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/229\/2\/413\/56680028\/jiad293.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/229\/2\/413\/56680028\/jiad293.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T22:08:02Z","timestamp":1708121282000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/229\/2\/413\/7233334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,28]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,7,28]]},"published-print":{"date-parts":[[2024,2,14]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiad293","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2,15]]},"published":{"date-parts":[[2023,7,28]]}}}